Bank of America Corp DE lifted its holdings in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 376.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 4,273,442 shares of the company's stock after purchasing an additional 3,376,446 shares during the quarter. Bank of America Corp DE owned 6.04% of Ventyx Biosciences worth $9,359,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds also recently modified their holdings of VTYX. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Ventyx Biosciences by 88.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 871,527 shares of the company's stock worth $1,909,000 after purchasing an additional 409,357 shares during the period. Renaissance Technologies LLC raised its position in shares of Ventyx Biosciences by 99.1% during the 4th quarter. Renaissance Technologies LLC now owns 624,500 shares of the company's stock worth $1,368,000 after buying an additional 310,800 shares in the last quarter. Boothbay Fund Management LLC lifted its stake in shares of Ventyx Biosciences by 472.2% in the 4th quarter. Boothbay Fund Management LLC now owns 314,891 shares of the company's stock worth $690,000 after acquiring an additional 259,863 shares during the period. Monaco Asset Management SAM bought a new position in shares of Ventyx Biosciences in the fourth quarter valued at approximately $526,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Ventyx Biosciences during the fourth quarter valued at approximately $436,000. Institutional investors own 97.88% of the company's stock.
Ventyx Biosciences Stock Performance
Shares of VTYX stock traded up $0.07 during mid-day trading on Tuesday, hitting $1.76. 1,268,583 shares of the stock traded hands, compared to its average volume of 1,337,672. Ventyx Biosciences, Inc. has a twelve month low of $0.78 and a twelve month high of $5.66. The company's 50-day simple moving average is $1.22 and its 200-day simple moving average is $1.73. The firm has a market cap of $125.24 million, a price-to-earnings ratio of -0.75 and a beta of 0.73.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.09. Analysts forecast that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.
About Ventyx Biosciences
(
Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Further Reading
Before you consider Ventyx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.
While Ventyx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
